Company profile
Novo Nordisk A/S logo

Novo Nordisk A/S

Pipeline30 assets

  • Glucose sensitive insulinNN1845 / Analogue / Diabetes
    Type 1 and 2 diabetesPhase 1
  • Ventus NLRP3iNN6022 / NLRP3 / Inhibitor / Diabetes
    CVDPhase 1
  • siRNA GalXC-GYS2siRNA / Diabetes
    siRNA GalXC-GYS2Phase 1
  • CNPCNP / Analogue / Diabetes
    Heart failurePhase 1
  • Amylin 355Analogue / Obesity
    ObesityPhase 1
  • Amylin 1213Analogue / Obesity
    ObesityPhase 1
  • SLC25A5SLC25A5 / siRNA / Obesity
    MASHPhase 1
  • Inno8Antibody fragment / Rare Blood Disorders
    HaemophiliaPhase 1
  • Subcutaneous ZenagamtideGLP-1 / amylin / Co-agonist / Diabetes / Obesity
    Subcutaneous ZenagamtidePhase 2ObesityPhase 2
  • Monlunabant in DKDCB1 receptor / Small molecule / Diabetes
    Diabetic Kidney Disease (DKD)Phase 2
  • Oral ZenagamtideGLP-1 / amylin / Co-agonist / Diabetes / Obesity
    DiabetesPhase 2ObesityPhase 2
  • CDR132LmiR-132 / Antisense oligonucleotide / Diabetes
    Heart failure with reduced ejection fraction (HFrEF)Phase 2
  • UBT251 (GGG tri-agonist)Obesity
    ObesityPhase 2
  • TripleGLP1 / GIP / amylin / Tri-agonist / Obesity
    ObesityPhase 2
  • MonlunabantINV-202 / CB1 receptor / Small molecule / Obesity
    ObesityPhase 2
  • NDecEPI01 / Rare Blood Disorders
    Sickle cell disease / An oral combination of decitabine and tetrahydrouridine. Project is developed in collaboration with EpiDestiny.Phase 2
  • EtavopivatRare Blood Disorders
    ThalassemiaPhase 2
  • CagriSema in T2DNN9388 / Analogue / Diabetes
    Type 2 diabetesPhase 3
  • Ziltivekimab ASCVDNN6018 / Diabetes
    Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD) and inflammationPhase 3
  • CoramitugPRX004 / Diabetes
    ATTR CardiomyopathyPhase 3
  • Ziltivekimabin HFpEFDiabetes
    Heart failure with preserved ejection fraction (HFpEF)Phase 3
  • Ziltivekimab AMIDiabetes
    Acute Myocardial infarction (AMI)Phase 3
  • CagrilintideAnalogue / Obesity
    ObesityPhase 3
  • Efruxifermin in MASHFGF21 / Analogue / Obesity
    MASHPhase 3
  • Etavopivat (Sickle Cell Disease)Small molecule / Rare Blood Disorders
    Sickle Cell DiseasePhase 3
  • IcosemaNN1535 / Analogue / Diabetes
    Type 2 diabetes / A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment.Filed
  • Insulin icodecNN1436 / Analogue / Diabetes
    DiabetesFiled
  • CagriSemaNN9898 / Analogue / Obesity
    ObesityFiled
  • Semaglutide 7.2 mgAnalogue / Obesity
    ObesityFiled
  • DenecimigMim8 / Inhibitor / Rare Blood Disorders
    Haemophilia A with or without inhibitors / A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis of haemophilia A regardless of inhibitor status.Filed

Latest news0 items

All news

No recent headlines yet.

New company coverage will appear here as soon as it is picked up.

Novo Nordisk A/S • Endpoint Arena